EUVIMEDEUVIMED entdecken
Crossref

Drug-Excipient Compatibility Testing of Cilostazol Using FTIR and DSC Analysis

Syrine Faith Diño, Alia Denise Edu, Ralph Gean Francisco, Emmanuel Gutierrez, Perlita Crucis, April Mergelle Lapuz, Rogie Royce Carandang, Kevin Jace Miranda

Philippine Journal of Science · 31.10.2023 · 152 (6A)

DOI: 10.56899/152.6a.08 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Philippine Journal of Science, online erschienen am 31.10.2023. Verfasst von Syrine Faith Diño und 7 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cilostazol possesses pharmacological restrictions, such as its absorption being limited by its dissolution rate, and formulation studies must be employed accordingly to generate an optimized formulation. A drug-excipient compatibility analysis is conducted to determine any interactions that may affect the formulation in order to guarantee the stability, bioavailability, and manufacturability of solid dosage forms. To identify any incompatibilities, cilostazol alone and in combination with the individual excipients such as microcrystalline cellulose, crospovidone, magnesium stearate, isopropyl alcohol, sodium lauryl sulfate, polyvinylpyrrolidone K30, and corn starch were subjected to Fourier-transform infrared spectroscopy (FTIR) equipped with an attenuated total reflectance method and heat-flow differential scanning calorimetry (DSC) with a temperature ranging from 30–400 °C at 10 °C/min ramp rate. The FTIR analysis of cilostazol alone and combined with excipients revealed no evidence of chemical or physical instability. Minor changes in the appearance of the absorbance bands in the FTIR comparison can be seen primarily due to the chemical characterization of the excipients, but the characteristic peaks of cilostazol were still present. As for DSC compatibility analysis, the % difference in cilostazol's principal peak temperature alone and with excipients showed no significant change. This implies that no incompatibilities exist between cilostazol and the excipients.

Zitieren

APA

Diño, S. F., Edu, A. D., Francisco, R. G., Gutierrez, E., Crucis, P., Lapuz, A. M., Carandang, R. R., & Miranda, K. J. (2023). Drug-Excipient Compatibility Testing of Cilostazol Using FTIR and DSC Analysis. Philippine Journal of Science, 152(6A). https://doi.org/10.56899/152.6a.08

Vancouver

Diño SF, Edu AD, Francisco RG, Gutierrez E, Crucis P, Lapuz AM, et al. Drug-Excipient Compatibility Testing of Cilostazol Using FTIR and DSC Analysis. Philippine Journal of Science. 2023;152(6A). doi:10.56899/152.6a.08

BibTeX
@article{Dio2023,
  author = {Diño, Syrine Faith and Edu, Alia Denise and Francisco, Ralph Gean and Gutierrez, Emmanuel and Crucis, Perlita and Lapuz, April Mergelle and Carandang, Rogie Royce and Miranda, Kevin Jace},
  title = {Drug-Excipient Compatibility Testing of Cilostazol Using FTIR and DSC Analysis},
  journal = {Philippine Journal of Science},
  year = {2023},
  volume = {152},
  number = {6A},
  doi = {10.56899/152.6a.08}
}
Kostenlos starten →